We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Helix BioPharma Reports Issuance of U.S. Patent for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47
Product News

Helix BioPharma Reports Issuance of U.S. Patent for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47

Helix BioPharma Reports Issuance of U.S. Patent for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47
Product News

Helix BioPharma Reports Issuance of U.S. Patent for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Helix BioPharma Reports Issuance of U.S. Patent for the Lung Cancer-Specific Antibody Used in Its Drug Candidate L-DOS47"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Helix BioPharma Corp., has announced the issuance of a patent (U.S. Patent No. 7,872,105 B2) by the United States Patent & Trademark Office for the non-small cell lung cancer-specific antibody component of its L-DOS47 drug candidate. As previously announced, the National Research Council of Canada ("NRC") has granted Helix the right to use this antibody in combination with its DOS47 technology under a worldwide exclusive license agreement that extends to the full term of the applicable patents.

L-DOS47 is the Company's first therapeutic immunoconjugate drug candidate under development based upon its novel DOS47 technology, which is designed to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction. L-DOS47 is intended to offer an innovative approach to the first-line treatment of inoperable, locally advanced, recurrent or metastatic NSCLC.

L-DOS47 combines Helix's DOS47 technology with NRC's highly specialized camelid-derived single domain antibody, which is designed to identify a unique CEACAM6 antigenic site predominantly associated with NSCLC cells.

"We congratulate the NRC," said Donald Segal Ph.D., Chairman & CEO of Helix. "This patent protects the antibody entity that is used to construct L-DOS47, and in turn adds significant strength to L-DOS47's patent protection."

Helix recently announced on February 7th, 2011 that it had received approval from the U.S. Food and Drug Administration to conduct a U.S. Phase I clinical study with L-DOS47. Helix also recently announced on February 24th, 2011 that it had filed a European clinical trial application seeking regulatory approval to also conduct a Phase I/II clinical study with L-DOS47.

Advertisement